- The FDA approves Shire's (NASDAQ:SHPG) Vyvanse (lisdexamfetamine dimesylate) for the treatment of adult patients with binge-eating disorder, a condition characterized by recurrent episodes of compulsive overeating even when the patient does not feel hungry.
- Binge-eating disorder can lead to weight gain and health problems related to obesity, but it is not approved or recommended for weight loss.
- Vyvanse was approved for sale in the U.S. in 2007 for the treatment of attention deficit hyperactivity disorder (ADHD) in patients at least six years old.